Tag Archives: NASDAQ:AXGT

Chardan Capital Remains a Buy on Axovant Gene Therapies (AXGT)

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Axovant Gene Therapies (AXGT – Research Report) on August 14 and set a price target of $12.50. The company’s shares closed last Friday at $3.05. According to TipRanks.com, Amusa is

Oppenheimer Remains a Hold on Axovant Gene Therapies (AXGT)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Axovant Gene Therapies (AXGT – Research Report). The company’s shares closed last Wednesday at $3.45. According to TipRanks.com, Olson has 0 stars on 0-5 stars ranking

Axovant Gene Therapies (AXGT) Receives a Rating Update from a Top Analyst

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Axovant Gene Therapies (AXGT – Research Report), with a price target of $15.00. The company’s shares closed last Wednesday at $3.40. According to TipRanks.com, Amusa

Chardan Capital Thinks Axovant Gene Therapies’ Stock is Going to Recover

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Axovant Gene Therapies (AXGT – Research Report) today and set a price target of $13.50. The company’s shares closed last Wednesday at $2.67, close to its 52-week low of $1.41.

Oppenheimer Keeps a Hold Rating on Axovant Gene Therapies (AXGT)

Oppenheimer analyst Jay Olson maintained a Hold rating on Axovant Gene Therapies (AXGT – Research Report) today. The company’s shares closed last Monday at $4.14, close to its 52-week low of $3.55. According to TipRanks.com, Olson is ranked 0 out

Cowen & Co. Maintains a Hold Rating on Axovant Gene Therapies (AXGT)

In a report released today, Ritu Baral from Cowen & Co. maintained a Hold rating on Axovant Gene Therapies (AXGT – Research Report). The company’s shares opened today at $6.43, close to its 52-week low of $3.81. According to TipRanks.com,